VOR News

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors

Vor Bio Announces $150 Million Private Placement

Vor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Vor Bio Announces Pricing of Public Offering of $100 Million of Common Stock

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

Telitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in China

Vor Bio to Participate in Upcoming Investor Conferences